Is VRNA or RYLD a better dividend investment in 2026?

VRNA currently yields 1.87% with a 5% 5-year dividend growth rate. RYLD yields 12.14% with 5% growth. The better choice depends on your goal: RYLD offers higher current income.

What is the dividend yield difference between VRNA and RYLD?

VRNA has a forward dividend yield of 1.87% ($2.00/share annually). RYLD yields 12.14% ($1.81/share annually). The yield gap is 10.27 percentage points.

Home › Compare › VRNA vs RYLD

VRNA vs RYLD: Dividend Comparison 2026

VRNA yields 1.87% · RYLD yields 12.14%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 RYLD wins by $22.1K in total portfolio value

INVESTMENT

TIME HORIZON10 years

VRNA

● Live price

1.87%

Share price

$106.91

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$22.4K

Annual income

$211.14

Full VRNA calculator →

RYLD

● Live price

12.14%

Share price

$14.95

Annual div

$1.81

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$44.5K

Annual income

$2,587.35

Full RYLD calculator →

Portfolio growth — VRNA vs RYLD

📍 RYLD pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	VRNA	RYLD
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, VRNA + RYLD cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

VRNA pays

RYLD pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

VRNA

Annual income on $10K today (after 15% tax)

$159.01/yr

After 10yr DRIP, annual income (after tax)

$179.47/yr

RYLD

Annual income on $10K today (after 15% tax)

$1,031.60/yr

After 10yr DRIP, annual income (after tax)

$2,199.25/yr

At 15% tax rate, RYLD beats the other by $2,019.78/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of VRNA + RYLD for your $10,000?

VRNA: 50%RYLD: 50%

100% RYLD50/50100% VRNA

Portfolio after 10yr

$33.5K

Annual income

$1,399.24/yr

Blended yield

4.18%

📊

Analyst Conviction Gap

Where Wall Street is most bullish on VRNA right now

VRNA

Analyst Ratings

Buy

Hold

Consensus: Buy

Price Target

$75.73

-29.2% upside vs current

Range: $26.00 — $170.00

Altman Z

111.3

Piotroski

3/9

RYLD

No analyst data

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

VRNA buys

RYLD buys

No recent congressional trades found for VRNA or RYLD in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricVRNARYLD

Forward yield	1.87%	12.14% ✓
Annual dividend / share	$2.00 ✓	$1.81
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	0%
Portfolio after 10y	$22.4K	$44.5K ✓
Annual income after 10y	$211.14	$2,587.35 ✓
Total dividends collected	$2.0K	$18.8K ✓
Payment frequency	quarterly	quarterly
Sector	Stock	ETF

Year-by-year: VRNA vs RYLD ($10,000, DRIP)

Year	VRNA Portfolio	VRNA Income/yr	RYLD Portfolio	RYLD Income/yr	Gap
1← crossover	$10,887	$187.07	$11,914	$1,213.65	$1.0K → RYLD
2	$11,840	$190.34	$14,099	$1,351.30	$2.3K → RYLD
3	$12,862	$193.45	$16,580	$1,494.55	$3.7K → RYLD
4	$13,958	$196.41	$19,384	$1,642.61	$5.4K → RYLD
5	$15,135	$199.21	$22,535	$1,794.70	$7.4K → RYLD
6	$16,396	$201.87	$26,063	$1,950.00	$9.7K → RYLD
7	$17,748	$204.38	$29,995	$2,107.69	$12.2K → RYLD
8	$19,197	$206.77	$34,361	$2,266.99	$15.2K → RYLD
9	$20,750	$209.02	$39,194	$2,427.12	$18.4K → RYLD
10	$22,414	$211.14	$44,525	$2,587.35	$22.1K → RYLD

VRNA vs RYLD: Complete Analysis 2026

VRNA — Stock

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. Verona Pharma plc was incorporated in 2005 and is headquartered in London, the United Kingdom.

Full VRNA Calculator →

RYLD — ETF

The Global X Russell 2000 Covered Call ETF (RYLD) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Cboe Russell 2000 BuyWrite Index.

Full RYLD Calculator →

📬

Get this VRNA vs RYLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

VRNA vs SCHD VRNA vs JEPI VRNA vs O VRNA vs KO VRNA vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.